Medication Self-Management Technology for Older Adults

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorUniversity of Illinois at Urbana-Champaign

About this trial

The goal of this feasibility study is to evaluate the preliminary impact of a mobile health application (app) called bpMedManage-R, designed to support hypertension medication self-management in persons with mild cognitive impairment (PwMCI) who live alone. The main questions this study aims to answer are whether the bpMedManage-R app shows preliminary impact on medication-related self-regulation (the ability to consistently take medications as prescribed) and self-efficacy (confidence in independently managing medication use). Participants will be randomized after a baseline assessment to the bpMedManage-R Immediate Group or the bpMedManage-R Delayed Group. Participants assigned to the Immediate Group will complete a 4-week baseline adherence period, at the end of which they will enter the intervention phase. A remote training session will be conducted to initiate the intervention phase, during which participants will download the app, learn to use it, and set up their medication schedule and reminders within the app with support from the study team. They will then use the app for 8 weeks to self-manage their medications, take part in brief weekly check-ins to review progress, and complete Outcome Assessment 1 at the end of the 8-week intervention phase. Participants assigned to the Delayed Group will complete a 12-week baseline adherence period, at the end of which they will complete Outcome Assessment 1. Subsequently, they will enter the intervention phase and will follow a process similar to that of the Immediate Group. At the end of the 8-week intervention phase, they will complete Outcome Assessment 2. Researchers will compare participants who receive the bpMedManage-R app intervention immediately to those assigned to the delayed control group.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 60+

Fluent in English

Adequate visual and auditory acuity

Community dwelling

Disqualifiers

Diagnosis of dementia

Major communication difficulties

Trial design

Design model

Parallel

Treatments tested in this trial

  • Immediate Intervention Arm

    Other intervention

    Participants will first complete a 4 week baseline medication adherence monitoring period. After this period, they will attend a video conferencing session with the research team to receive guidance on downloading and using the bpMedManage R app. They will also set personalized goals for self-monitoring their medication daily and weekly using the app. Participants will then use the app for 8 weeks to monitor their medication adherence along with brief weekly check ins to address questions or technical issues. At the end of the 8 week intervention, participants will complete a final assessment.

  • Delayed Intervention Arm

    Other intervention

    Participants will first complete a 12 week baseline medication adherence monitoring period. At the end of this period, they will attend a video conferencing session with the research team during which they will complete a brief assessment and receive guidance on downloading and using the bpMedManage R app. They will also set personalized goals for self-monitoring their medication daily and weekly using the app. Participants will then use the app for 8 weeks, along with brief weekly check ins to address questions or technical issues. At the end of the 8 week intervention, they will complete a final assessment.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: bpMedManage R Immediate GroupExperimental treatment 1 intervention
Group B: bpMedManage R Delayed GroupOther 1 intervention

Trial outcomes

Primary outcomes

1

Change in Self-regulation Measured by Adapted Short Self-Regulation Questionnaire (SSRQ)

A 31-item measure of the ability to regulate behavior in order to achieve desired future outcomes.

Time frame
Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention
2

Change in Medication Usage Self-efficacy Measured by Medication Usage Self-Efficacy (MUSE) questionnaire

A brief 8-item tool that measures how confident a person is in understanding and taking their prescribed medications.

Time frame
Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention
3

Change in Medication Usage Self-efficacy Measured by Medication Adherence Self-Efficacy Scale-revised (MASES-R)

A13-item questionnaire that measures a person's confidence in taking their medication even when faced with difficult situations.

Time frame
Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Illinois at Urbana-Champaign

Lead sponsor

Arizona State University

Collaborator

This trial is not recruiting at the moment. You can still explore other options: